CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 1.09 USD -0.91% Market Closed
Market Cap: 85.3m USD
Have any thoughts about
CytomX Therapeutics Inc?
Write Note

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 5.39 USD with a low forecast of 3.28 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.28 USD
201% Upside
Average
Price Target
5.39 USD
395% Upside
Highest
Price Target
8.4 USD
671% Upside

CTMX Last Price Targets
CytomX Therapeutics Inc

The latest public price target was made on Nov 8, 2024 by Joseph Catanzaro from Piper Sandler , who expects CTMX stock to rise by 198% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Joseph Catanzaro
Piper Sandler
3.25 USD
Upside 198%
1 month ago
Nov 8, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at Piper Sandler
StreetInsider
Etzer Darout
BMO Capital
3.68 USD
Upside 238%
1 month ago
Nov 8, 2024
CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital
StreetInsider
Etzer Darout
BMO Capital
3.56 USD
Upside 227%
4 months ago
Aug 9, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital
StreetInsider
Joseph Catanzaro
Piper Sandler
3.5 USD
Upside 221%
6 months ago
May 27, 2024
CytomX Therapeutics upgraded to Overweight from Neutral at Piper Sandler
TheFly
Robert Driscoll
Wedbush
8 USD
Upside 634%
7 months ago
May 9, 2024
Wedbush Upgrades CytomX Therapeutics (CTMX) to Outperform
StreetInsider
Etzer Darout
BMO Capital
3.59 USD
Upside 229%
7 months ago
May 9, 2024
CytomX Therapeutics (CTMX) PT Raised to $3.59 at BMO Capital
StreetInsider
Roger Song
Jefferies
8 USD
Upside 634%
7 months ago
May 5, 2024
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
TheFly
Roger Song
Jefferies
2.5 USD
Upside 129%
9 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24'
StreetInsider
Etzer Darout
BMO Capital
3.25 USD
Upside 198%
9 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at BMO Capital, 'Pipeline Updates Broadly in Line'
StreetInsider
Show More Price Targets
Show Less Price Targets
Joseph Catanzaro
Piper Sandler
Price Target 3.25 USD
Upside/Downside 198%
View Source
Etzer Darout
BMO Capital
Price Target 3.68 USD
Upside/Downside 238%
View Source
Etzer Darout
BMO Capital
Price Target 3.56 USD
Upside/Downside 227%
View Source
Joseph Catanzaro
Piper Sandler
Price Target 3.5 USD
Upside/Downside 221%
View Source
Robert Driscoll
Wedbush
Price Target 8 USD
Upside/Downside 634%
View Source
Etzer Darout
BMO Capital
Price Target 3.59 USD
Upside/Downside 229%
View Source
Roger Song
Jefferies
Price Target 8 USD
Upside/Downside 634%
View Source
Roger Song
Jefferies
Price Target 2.5 USD
Upside/Downside 129%
View Source
Etzer Darout
BMO Capital
Price Target 3.25 USD
Upside/Downside 198%
View Source
Show More Price Targets
Show Less Price Targets
CytomX Therapeutics Inc Competitors:
Price Targets
ALGS
Aligos Therapeutics Inc
73% Upside
CPRX
Catalyst Pharmaceuticals Inc
55% Upside
MDXG
MiMedx Group Inc
46% Upside
GNS
Genus PLC
59% Upside
MAAT
Maat Pharma SA
109% Upside
4882
Perseus Proteomics Inc
38% Upside
VCEL
Vericel Corp
9% Upside
SVRA
Savara Inc
202% Upside

Revenue
Forecast

Revenue Estimate
CytomX Therapeutics Inc

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 4 years is -19%.

38%
Past Growth
-19%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
5.39 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 5.39 USD with a low forecast of 3.28 USD and a high forecast of 8.4 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-19%

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 4 years is -19%.

Back to Top